🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

EU, Gilead Reach Deal on Supply of Antiviral Drug Remdesivir

Published 07/29/2020, 06:41 AM
Updated 07/29/2020, 07:18 AM
© Reuters.  EU, Gilead Reach Deal on Supply of Antiviral Drug Remdesivir
GILD
-

(Bloomberg) --

The European Union reached an agreement with Gilead Sciences Inc (NASDAQ:GILD). for supplies of the company’s antiviral drug remdesivir to combat the coronavirus.

The European Commission signed a 63 million-euro ($74 million) contract with Gilead for batches of Veklury -- the brand name for remdesivir -- to be made available to EU countries and the U.K. starting in early August.

The deal will ensure the treatment of around 30,000 patients with “severe” Covid-19 symptoms, the commission, the 27-nation EU’s executive arm, said in an emailed statement on Wednesday in Brussels. The commission also said it’s preparing a joint procurement for further supplies of the medicine to cover extra needs as of October.

“The commission is leaving no stone unturned in its efforts to secure access to safe and efficient treatments,” EU Health Commissioner Stella Kyriakides said in the statement.

©2020 Bloomberg L.P.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.